ACADIA Pharmaceuticals Inc. $ACAD Shares Purchased by GSA Capital Partners LLP

GSA Capital Partners LLP raised its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 210.1% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 75,902 shares of the biopharmaceutical company’s stock after purchasing an additional 51,428 shares during the period. GSA Capital Partners LLP’s holdings in ACADIA Pharmaceuticals were worth $1,620,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the company. JPMorgan Chase & Co. boosted its position in shares of ACADIA Pharmaceuticals by 4.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 325,921 shares of the biopharmaceutical company’s stock worth $6,955,000 after buying an additional 13,984 shares in the last quarter. State of New Jersey Common Pension Fund D purchased a new position in ACADIA Pharmaceuticals during the 3rd quarter valued at about $1,831,000. PNC Financial Services Group Inc. raised its position in ACADIA Pharmaceuticals by 11.2% during the third quarter. PNC Financial Services Group Inc. now owns 5,323 shares of the biopharmaceutical company’s stock worth $114,000 after acquiring an additional 534 shares during the last quarter. Public Sector Pension Investment Board lifted its holdings in shares of ACADIA Pharmaceuticals by 15.3% in the third quarter. Public Sector Pension Investment Board now owns 486,988 shares of the biopharmaceutical company’s stock valued at $10,392,000 after purchasing an additional 64,736 shares in the last quarter. Finally, Illinois Municipal Retirement Fund lifted its holdings in shares of ACADIA Pharmaceuticals by 10.1% in the third quarter. Illinois Municipal Retirement Fund now owns 70,683 shares of the biopharmaceutical company’s stock valued at $1,508,000 after purchasing an additional 6,473 shares in the last quarter. Hedge funds and other institutional investors own 96.71% of the company’s stock.

Insider Activity at ACADIA Pharmaceuticals

In related news, EVP Jennifer J. Rhodes sold 6,950 shares of the firm’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $23.38, for a total value of $162,491.00. Following the sale, the executive vice president directly owned 7,609 shares of the company’s stock, valued at approximately $177,898.42. This trade represents a 47.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 28.30% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

ACAD has been the subject of a number of recent research reports. Royal Bank Of Canada dropped their price objective on shares of ACADIA Pharmaceuticals from $35.00 to $31.00 and set an “outperform” rating for the company in a research note on Tuesday, February 3rd. Citigroup increased their target price on ACADIA Pharmaceuticals from $33.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. Citizens Jmp reissued a “market outperform” rating and set a $34.00 price target on shares of ACADIA Pharmaceuticals in a research report on Tuesday, February 3rd. UBS Group upped their price objective on ACADIA Pharmaceuticals from $35.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Finally, Piper Sandler set a $37.00 price objective on ACADIA Pharmaceuticals in a research report on Tuesday, December 16th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $30.95.

ACADIA Pharmaceuticals Trading Up 4.2%

ACADIA Pharmaceuticals stock opened at $22.95 on Wednesday. The stock has a fifty day moving average price of $25.93 and a 200 day moving average price of $24.44. ACADIA Pharmaceuticals Inc. has a 52 week low of $13.40 and a 52 week high of $28.35. The firm has a market capitalization of $3.88 billion, a P/E ratio of 14.81, a PEG ratio of 7.73 and a beta of 0.66.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.